表紙:人工関節感染症:開発中の薬剤
市場調査レポート
商品コード
410971

人工関節感染症:開発中の薬剤

Prosthetic joint infections (Musculoskeletal) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 80 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
人工関節感染症:開発中の薬剤
出版日: 2021年12月30日
発行: Global Markets Direct
ページ情報: 英文 80 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

人工関節感染症 (PJI)は人工関節移植の中でも最も深刻な合併症の一つです。症状は、関節の痛みやこわばり、腫れ、患部周辺の発赤、疲労および発熱などです。危険因子としては、年齢、以前の関節形成術、栄養不良状態、肥満、糖尿病および進行したHIV疾患などがあります。治療は抗菌療法を行います。

当レポートでは、人工関節感染症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

人工関節感染症 概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Cempra Inc
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Telephus Medical LLC

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Prosthetic Joint infections, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Prosthetic Joint infections - Pipeline by Adaptive Phage Therapeutics Inc, 2021
  • Prosthetic Joint infections - Pipeline by Arietis Corp, 2021
  • Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, 2021
  • Prosthetic Joint infections - Pipeline by ContraFect Corp, 2021
  • Prosthetic Joint infections - Pipeline by Integrated BioTherapeutics Inc, 2021
  • Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, 2021
  • Prosthetic Joint infections - Pipeline by Nabriva Therapeutics Plc, 2021
  • Prosthetic Joint infections - Pipeline by Osteal Therapeutics Inc, 2021
  • Prosthetic Joint infections - Pipeline by Peptilogics Inc, 2021
  • Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, 2021
  • Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, 2021
  • Prosthetic Joint infections - Dormant Projects, 2021
  • Prosthetic Joint infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Prosthetic Joint infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13201IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic Joint infections - Drugs In Development, 2021, provides an overview of the Prosthetic Joint infections (Musculoskeletal Disorders) pipeline landscape.

Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue, and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic Joint infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic Joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 1, 6 and 1 respectively.

Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic Joint infections (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prosthetic Joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Prosthetic Joint infections - Overview
  • Prosthetic Joint infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Prosthetic Joint infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Prosthetic Joint infections - Companies Involved in Therapeutics Development
  • Prosthetic Joint infections - Drug Profiles
  • Prosthetic Joint infections - Dormant Projects
  • Prosthetic Joint infections - Discontinued Products
  • Prosthetic Joint infections - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer